# EDGAR Filing Document

**Accession Number:** 0002124444
**File Stem:** 0001104659-26-036225
**Filing Date:** 2026-3
**Character Count:** 11073
**Document Hash:** 092975e9e70d4c5c80b647dd9e5dcbb9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-036225.hdr.sgml**: 20260327

**ACCESSION NUMBER**: 0001104659-26-036225

**CONFORMED SUBMISSION TYPE**: 3/A

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260327

**DATE AS OF CHANGE**: 20260327

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Prego Roberto
- **CENTRAL INDEX KEY:** 0002124444

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39950
- **FILM NUMBER:** 26808483

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** DR. NEERGAARDS VEJ 5F
- **CITY:** HORSHOLM
- **PROVINCE COUNTRY:** G7
- **ZIP:** DK-2970
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evaxion A/S
- **CENTRAL INDEX KEY:** 0001828253
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** DR NEERGAARDS VEJ 5F
- **CITY:** HOERSHOLM
- **PROVINCE COUNTRY:** G7
- **BUSINESS PHONE:** 4552656554

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** DR NEERGAARDS VEJ 5F
- **CITY:** HOERSHOLM
- **PROVINCE COUNTRY:** G7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Evaxion Biotech A/S
- **DATE OF NAME CHANGE:** 20201014

## Exhibit 24.1

**Exhibit 24.1**

**LIMITED POWER OF ATTORNEY**

The undersigned hereby constitutes and appoints Michael Baird and Carly Antonioli, and each of them individually, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of Evaxion A/S (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by each such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as each such attorney-in-fact may approve in each such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of March 16, 2026.

---

| |
|:---|
| Signed and acknowledged: |
| Prego Roberto |
| /s/ Roberto Prego |
| Signature |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Prego Roberto<br><sub>(Last) (First) (Middle)</sub><br>DR. NEERGAARDS VEJ 5F<br><sub>(Street)</sub><br>HORSHOLM, DENMARK DK-2970<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Evaxion A/S [ EVAX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares |  |  |  |  |  |  |  | 494410 | D |  |
| Ordinary Shares |  |  |  |  |  |  |  | 676620 | I | Prego Fidaco Investment<sup>(1)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Warrants<sup>(2)</sup> | $0.74 |  |  |  |  |  |  | 2023-12-21 | 2026-12-21 | Ordinary Shares | 91912 |  |  | D |  |
| Warrants<sup>(3)</sup> | $0.059 |  |  |  |  |  |  | 2025-01-31 | 2030-01-31 | Ordinary Shares | 46100 |  |  | D |  |
| Warrants | $0.1 |  |  |  |  |  |  | 2016-01-01 | 2036-12-31 | Ordinary Shares | 100260 |  |  | I | Prego Fidaco Investment<sup>(1)</sup> |
| Warrants | $0.1 |  |  |  |  |  |  | 2017-01-01<sup>(4)</sup> | 2036-12-31 | Ordinary Shares | 7416 |  |  | D |  |
| Warrants | $0.1 |  |  |  |  |  |  | 2017-01-01<sup>(4)</sup> | 2036-12-31 | Ordinary Shares | 14832 |  |  | I | Prego Fidaco Investment<sup>(1)</sup> |
| Warrants | $0.1 |  |  |  |  |  |  | 2018-01-01<sup>(4)</sup> | 2036-12-31 | Ordinary Shares | 12384 |  |  | D |  |
| Warrants | $0.1 |  |  |  |  |  |  | 2018-01-01<sup>(4)</sup> | 2036-12-31 | Ordinary Shares | 4356 |  |  | I | Prego Fidaco Investment<sup>(1)</sup> |
| Warrants | $0.1 |  |  |  |  |  |  | 2019-01-01 | 2031-12-31 | Ordinary Shares | 7128 |  |  | D |  |
| Warrants | $0.1 |  |  |  |  |  |  | 2020-01-01 | 2031-12-31 | Ordinary Shares | 7236 |  |  | D |  |
| Warrants | $5.38 |  |  |  |  |  |  | 2021-01-01 | 2031-12-31 | Ordinary Shares | 4583 |  |  | D |  |
| Warrants | $2.23 |  |  |  |  |  |  | 2022-01-01<sup>(4)</sup> | 2031-12-31 | Ordinary Shares | 5000 |  |  | D |  |
| Warrants | $0.75 |  |  |  |  |  |  | 2023-01-01<sup>(4)</sup> | 2031-12-31 | Ordinary Shares | 5000 |  |  | D |  |
| Warrants | $0.4 |  |  |  |  |  |  | 2024-01-01<sup>(4)</sup> | 2031-12-31 | Ordinary Shares | 20000 |  |  | D |  |
| Warrants | $0.07 |  |  |  |  |  |  | 2024-01-01<sup>(4)</sup> | 2031-12-31 | Ordinary Shares | 25000 |  |  | D |  |

---

### Footnotes:

(1) Mr. Prego's father is a control person of this entity.

(2) Warrants pursuant to private placement that closed 12/21/2023.

(3) Warrants pursuant to public offering that closed 1/31/2025.

(4) Vesting is 1/12 per month over 12 months from the initial exercise date indicated.

**Remarks:**
Exhibit List - Exhibit 24.1 Power of Attorney. This Form 3/A amends the Form 3 filed on March 18, 2026, which reported Mr. Prego's initial holdings using the Issuer's CIK number as an interim measure, pending receipt of Mr. Prego's new filer CIK codes. This Form 3/A has been filed using Mr. Prego's CIK codes and reflects him as the Reporting Owner, with no alteration to his beneficial ownership.

**Signature:** /s/ Michael Baird, Attorney-in-Fact  
**Date:** 2026-03-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**